NASDAQ NMS - GLOBAL MARKET · ALLO
+1.81% · +$0.0371 · Vol 4.7M
Market closed · last close 4:00 PM ET · price as of 19:57:06 ET
Allogene Therapeutics Inc

Allogene Therapeutics Inc

Biotechnology
$2.09
Card
Relationship Map

Veridion Score

BETAMEDIUM CONF · 5/6 factorsMethodology
Sentiment absence reason unknown
ALLO
Allogene Therapeutics Inc
Mon Aug 17 · last completed session · Markets closed · resumes Tue 9:30 ET
BUY BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

68/ 100
Veridion Score
BUY BIAS · MEDIUM confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5/6 factors with data · Mon Aug 17 · last completed session · Markets closed · resumes Tue 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is ALLO moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading ALLO catalysts
About Allogene Therapeutics Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2018
Employees
152
Country
US

Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$2.05
Day high
$2.10
Day low
$2.02
Previous close
$2.05
52W high
$3.06
-31.79% from high
52W low
$1.05
52% of range
Market cap
$708.3M
EPS
$-0.7800
Beta
0.71
Shares out
345.5M
Volume
4.7M
0.72× rel vol
Avg volume
6.5M
VWAP
$2.07
Price history computed in-house
1W
-1.55%
1M
+16.60%
3M
+9.85%
1Y
+91.48%
YTD
+52.34%
SMA 50 $1.95 · above
SMA 200 $1.91 · above
52W position 52%

ALLO overview

Veridion Score
68
Daily close · 2026-08-17
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around ALLO.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading ALLO Form 4 filings
Public disclosures

Congress activity in ALLO

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for ALLO in the cached public ledger.

Federal contracts

ALLO contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ALLO in this window.
Lobbying spend

ALLO lobbying filings, year to date.

Registered lobbying filings matched to Allogene Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ALLO in this window.
Loading news for ALLO
Analyst ratings
Sovereign unlock shows live analyst consensus for ALLO.
Options
Sovereign unlock shows live options positioning for ALLO.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.